Market closedNon-fractional
PROCEPT BioRobotics/PRCT
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About PROCEPT BioRobotics
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.
Ticker
PRCT
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Equipment and Supplies
Headquarters
San Jose, United States
Employees
626
Website
www.procept-biorobotics.com
PRCT Metrics
BasicAdvanced
$3.2B
Market cap
-
P/E ratio
-$2.12
EPS
1.01
Beta
-
Dividend rate
Price and volume
Market cap
$3.2B
Beta
1.01
Financial strength
Current ratio
8.517
Quick ratio
7.287
Long term debt to equity
30.179
Total debt to equity
31.548
Interest coverage (TTM)
-26.11%
Management effectiveness
Return on assets (TTM)
-20.31%
Return on equity (TTM)
-47.29%
Valuation
Price to revenue (TTM)
19.69
Price to book
12.3
Price to tangible book (TTM)
12.36
Price to free cash flow (TTM)
-24.4
Growth
Revenue change (TTM)
83.44%
Earnings per share change (TTM)
-3.71%
3-year revenue growth
125.05%
3-year earnings per share growth
-44.96%
What the Analysts think about PRCT
Analyst Ratings
Majority rating from 9 analysts.
PRCT Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$45M
2.30%
Net income
-$26M
-5.82%
Profit margin
-58.20%
-7.93%
PRCT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.56
-$0.51
-$0.54
-$0.51
-
Expected
-$0.57
-$0.51
-$0.44
-$0.56
-$0.52
Surprise
-1.97%
-0.86%
23.04%
-8.19%
-
PRCT News
AllArticlesVideos
PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy
GlobeNewsWire·2 weeks ago
PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024
GlobeNewsWire·1 month ago
PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PROCEPT BioRobotics stock?
PROCEPT BioRobotics (PRCT) has a market cap of $3.2B as of July 04, 2024.
What is the P/E ratio for PROCEPT BioRobotics stock?
The price to earnings (P/E) ratio for PROCEPT BioRobotics (PRCT) stock is 0 as of July 04, 2024.
Does PROCEPT BioRobotics stock pay dividends?
No, PROCEPT BioRobotics (PRCT) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next PROCEPT BioRobotics dividend payment date?
PROCEPT BioRobotics (PRCT) stock does not pay dividends to its shareholders.
What is the beta indicator for PROCEPT BioRobotics?
PROCEPT BioRobotics (PRCT) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell PROCEPT BioRobotics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.